Robert C. Goeltz II

2019 - Unity Biotechnology

In 2019, Robert C. Goeltz II earned a total compensation of $1.6M as Chief Financial Officer at Unity Biotechnology, a 79% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$166,100
Option Awards$853,916
Salary$400,000
Stock Awards$189,675
Other$11,200
Total$1,620,891

Goeltz received $853.9K in option awards, accounting for 53% of the total pay in 2019.

Goeltz also received $166.1K in non-equity incentive plan, $400K in salary, $189.7K in stock awards and $11.2K in other compensation.

Rankings

In 2019, Robert C. Goeltz II's compensation ranked 6,940th out of 13,971 executives tracked by ExecPay. In other words, Goeltz earned more than 50.3% of executives.

ClassificationRankingPercentile
All
6,940
out of 13,971
50th
Division
Manufacturing
2,653
out of 5,701
54th
Major group
Chemicals And Allied Products
967
out of 2,200
56th
Industry group
Drugs
817
out of 1,886
57th
Industry
Pharmaceutical Preparations
599
out of 1,398
57th
Source: SEC filing on April 24, 2020.

Goeltz's colleagues

We found three more compensation records of executives who worked with Robert C. Goeltz II at Unity Biotechnology in 2019.

2019

Keith Leonard

Unity Biotechnology

Chief Executive Officer

2019

Nathaniel David

Unity Biotechnology

President

2019

Jamie Dananberg

Unity Biotechnology

Chief Medical Officer

News

In-depth

You may also like